Is the current market and capital environment a new event for the board to respond to, or have we been in the doldrums for years?
Should poor valuation and lack of capital interest dictate a change in strategy?
Would a MPS deal or regional OA (China) deal give legitimacy to the markets, and thus put us in a superior position to do a CR?
Why do people think the MPS deal will be poor when Rennie said term sheets have gone to 30 parties at the AGM last year?
How many commercial transactions have been done in the pharma space, at much shorter time periods?
Its time for a deal. Fish or cut bait.
PAR. SP, page-64
-
- There are more pages in this discussion • 923 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $162.7K | 620.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25008 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 34768 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |